Literature DB >> 22540329

Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.

Juan-Manuel Sancho1, Mireia Morgades, Joan-Ramon Grifols, Jordi Juncà, Ramon Guardia, Susana Vives, Christelle Ferrà, Monsterrat Batlle, Anna Ester, David Gallardo, Fuensanta Millà, Evarist Feliu, Josep-Maria Ribera.   

Abstract

BACKGROUND AIMS: Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the administration of pre-emptive rescue mobilization.
METHODS: Data from the first mobilization schedule of 397 patients referred consecutively for autologous HSCT between 2000 and 2010 were collected. Poor mobilization was defined as the collection of < 2 × 10(6) CD34(+)cells/kg body weight (BW).
RESULTS: The median age was 53 years (range 4-70) and 228 (57%) were males. Diagnoses were multiple myeloma in 133 cases, non-Hodgkin's lymphoma in 114, acute myeloid leukemia or myelodysplastic syndrome in 81, Hodgkin's lymphoma in 42, solid tumors in 17 and acute lymphoblastic leukemia in 10. The mobilization regimen consisted of recombinant human granulocyte-colony-stimulating factor (G-CSF) in 346 patients (87%) and chemotherapy followed by G-CSF (C + G-CSF) in 51 (13%). Poor mobilization occurred in 105 patients (29%), without differences according to mobilization schedule. Diagnosis, previous therapy with purine analogs and three or more previous chemotherapy lines were predictive factors for poor mobilization. A CD34(+)cell count in PB > 13.8/μL was enough to ensure ≥ 2 × 10(6) CD34(+)cells/kg, with high sensitivity (90%) and specificity (91%).
CONCLUSIONS: The prevalence of poor mobilization was high, being associated with disease type, therapy with purine analogs and multiple chemotherapy regimens. The threshold of CD34(+) cell count in PB identified poor mobilizers, in whom the administration of immediate or pre-emptive plerixafor could be useful to avoid a second mobilization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22540329     DOI: 10.3109/14653249.2012.681042

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  13 in total

1.  Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

Authors:  Lauren Veltri; Aaron Cumpston; Alexandra Shillingburg; Sijin Wen; Jin Luo; Sonia Leadmon; Kathy Watkins; Michael Craig; Mehdi Hamadani; Abraham S Kanate
Journal:  Cytotherapy       Date:  2015-10-21       Impact factor: 5.414

Review 2.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

3.  A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.

Authors:  Gaofeng Zheng; Jingsong He; Zhen Cai; Donghua He; Yi Luo; Jimin Shi; Guoqing Wei; Jie Sun; Weiyan Zheng
Journal:  Oncol Lett       Date:  2019-12-03       Impact factor: 2.967

4.  Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.

Authors:  I Sánchez-Ortega; S Querol; M Encuentra; S Ortega; A Serra; J M Sanchez-Villegas; J R Grifols; M M Pujol-Balaguer; M Pujol-Bosch; J M Martí; T Garcia-Cerecedo; P Barba; J M Sancho; A Esquirol; J Sierra; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

5.  Stem cell mobilization in HIV seropositive patients with lymphoma.

Authors:  Alessandro Re; Chiara Cattaneo; Cristina Skert; Pascual Balsalobre; Mariagrazia Michieli; Mark Bower; Andrés J M Ferreri; Marcus Hentrich; José M Ribera; Bernardino Allione; Philipp Schommers; Silvia Montoto; Camillo Almici; Pierino Ferremi; Mario Mazzucato; Salvatore Gattillo; Salvatore Casari; Michele Spina; José L Diez-Martin; Umberto Tirelli; Giuseppe Rossi
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

6.  Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Authors:  Marc-Andrea Baertsch; Katharina Kriegsmann; Petra Pavel; Thomas Bruckner; Michael Hundemer; Mark Kriegsmann; Anthony D Ho; Hartmut Goldschmidt; Patrick Wuchter
Journal:  Transfus Med Hemother       Date:  2017-10-04       Impact factor: 3.747

7.  Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.

Authors:  Pellegrino Musto; Vittorio Simeon; Alberto Grossi; Francesca Gay; Sara Bringhen; Alessandra Larocca; Roberto Guariglia; Giuseppe Pietrantuono; Oreste Villani; Giovanni D'Arena; Carmela Cuomo; Clelia Musto; Fortunato Morabito; Maria Teresa Petrucci; Massimo Offidani; Elena Zamagni; Paola Tacchetti; Concetta Conticello; Giuseppe Milone; Antonio Palumbo; Michele Cavo; Mario Boccadoro
Journal:  Stem Cell Res Ther       Date:  2015-04-17       Impact factor: 6.832

8.  HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.

Authors:  C E Forristal; B Nowlan; R N Jacobsen; V Barbier; G Walkinshaw; C R Walkley; I G Winkler; J P Levesque
Journal:  Leukemia       Date:  2015-01-12       Impact factor: 11.528

9.  Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.

Authors:  R E Clark; J Bell; J O Clark; B Braithwaite; U Vithanarachchi; N McGinnity; T Callaghan; S Francis; R Salim
Journal:  Blood Cancer J       Date:  2014-10-31       Impact factor: 11.037

10.  A novel approach for the enumeration of peripheral blood stem cells suitable for transplantation.

Authors:  Winston Costa Pereira; Omar Alsuhaibani; Ghaleb Elyamany; Abdulaziz Al Abdulaaly
Journal:  J Transplant       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.